UCB Receives New European Commission Approvals for BIMZELX® (bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

- Bimekizumab is the first and only IL-17A and IL-17F inhibitor approved in the European Union for active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA)
- Approval in PsA is supported by two Phase 3 studies where bimekizumab showed improvements vs. placebo in joint and skin symptoms across biologic naive and TNF inhibitor-inadequate responder populations
- Approval in axSpA is supported by two Phase 3 studies where bimekizumab showed improvements vs. placebo in signs, symptoms and disease activity across the spectrum of disease

Brussels (Belgium), 7th June 2023 – 07:00 (CEST) – UCB, a global biopharmaceutical company, today announced that the European Commission (EC) has granted marketing authorisation for BIMZELX® (bimekizumab) for the treatment of adults with active psoriatic arthritis (PsA) and adults with active axial spondyloarthritis (axSpA) including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axSpA. These approvals in the European Union (EU) represent the first marketing authorizations for bimekizumab in PsA and axSpA worldwide, and the second and third indications for bimekizumab in the EU, following its approval for the treatment of moderate to severe plaque psoriasis in August 2021.1

“The European Commission’s parallel approval of bimekizumab in PsA and axSpA builds on the momentum created since its first approval in moderate to severe plaque psoriasis and marks an exciting milestone offering healthcare professionals and patients the first IL-17A and IL-17F inhibitor for treatment of these diseases,” said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB. “The extended approval for bimekizumab in the European Union reflects our commitment to address unmet patient needs, improve patient outcomes and raise standards of care.”

In PsA, bimekizumab is approved alone or in combination with methotrexate for the treatment of adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).1 In axSpA, bimekizumab is approved for the treatment of adults with active nr-axSpA with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs, and for the treatment of adults with active AS who have responded inadequately or are intolerant to conventional therapy.1

Bimekizumab in PsA: Highlights from BE OPTIMAL and BE COMPLETE
The EC approval in PsA is based on results from the Phase 3 BE OPTIMAL and BE COMPLETE studies.1,2,3 In the two studies, bimekizumab met the primary endpoint of ACR50 response at Week 16 vs. placebo, and all ranked secondary endpoints.1,2,3 Consistent results were seen across both biologic-naïve and TNF-inhibitor...
inadequate responder (TNFi-IR) populations.\textsuperscript{1,2,3} Clinical responses achieved at Week 16 were sustained up to Week 52 in BE OPTIMAL as assessed by ACR50, PASI90, PASI100 and Minimal Disease Activity (MDA).\textsuperscript{1}

- **Joint Symptoms, ACR50:** In bDMARD-naive and TNFi-IR patients, 44 percent (n=189/431) and 43 percent (n=116/267) receiving bimekizumab achieved the primary endpoint of ACR50 response at Week 16, respectively, vs. 10 percent (n=28/281) and 7 percent (n=9/133) receiving placebo (p<0.0001).\textsuperscript{2,3}

- **MDA:** In bDMARD-naive and TNFi-IR populations, 45 percent (n=194/431) and 44 percent (n=118/267) of patients receiving bimekizumab achieved the ranked secondary endpoint MDA at Week 16, respectively, vs. 13 percent (n=37/281) and 6 percent (n=8/133) receiving placebo (p<0.0001).\textsuperscript{2,3}

- **Skin Symptoms, PASI100:** In bDMARD-naive and TNFi-IR populations, 47 percent (n=103/176) and 59 percent (n=103/176) of patients with baseline psoriasis affecting $\geq 3$ percent body surface area receiving bimekizumab achieved complete skin clearance (PASI100; exploratory endpoint) at Week 16, respectively, vs. 2 percent (n=3/140) and 5 percent (n=4/88) receiving placebo.\textsuperscript{2,3}

“The approval of bimekizumab in psoriatic arthritis provides rheumatologists and dermatologists in the European Union with a new treatment option. Data from the Phase 3 clinical studies demonstrated the consistently high thresholds of disease control achieved with bimekizumab vs. placebo in patients with psoriatic arthritis who were biologic naïve or TNF inhibitor-inadequate responders,” said Professor Iain McInnes, University of Glasgow, College of Medical, Veterinary and Life Sciences, Glasgow, Scotland.

In BE OPTIMAL, the most frequent treatment-emergent adverse events (TEAEs; 3 percent or more) for patients on bimekizumab up to Week 16 were nasopharyngitis, upper respiratory tract infection, headache, diarrhoea, oral candidiasis, pharyngitis and hypertension.\textsuperscript{2} In BE COMPLETE, the most frequent TEAEs (2 percent or more) for patients on bimekizumab up to Week 16 were nasopharyngitis, oral candidiasis and upper respiratory tract infection.\textsuperscript{3}

**Bimekizumab in axSpA: Highlights from BE MOBILE 1 and BE MOBILE 2**

The EC approval in axSpA is based on results from the Phase 3 BE MOBILE 1 and BE MOBILE 2 studies.\textsuperscript{1,4} In the two studies, bimekizumab met the primary endpoint of Assessment of SpondyloArthritis international Society (ASAS) 40 response at Week 16 vs. placebo, and all ranked secondary endpoints.\textsuperscript{4} ASAS40 responses were consistent across TNFi-naïve and TNFi-inadequate responder patients.\textsuperscript{4} Clinical responses achieved at Week 16 were sustained in both nr-axSpA and AS patient populations up to Week 52 as assessed by ASAS40 and other endpoints.\textsuperscript{1,5}

- **ASAS40:** In nr-axSpA and AS populations, 47.7 percent (n=61/128) and 44.8 percent (n=99/221) respectively of patients receiving bimekizumab achieved the primary endpoint of ASAS40 response at Week 16, vs. 21.4 percent (n=27/126) and 22.5 percent (n=25/111) receiving placebo (p<0.001).\textsuperscript{4}

- **Low Disease Activity:** Low disease activity (ASDAS<2.1 combining ASDAS-Inactive Disease and ASDAS-Low Disease, an exploratory endpoint) was achieved at Week 16 by 46.2 percent of nr-axSpA patients and 44.9 percent of AS patients vs. 20.6 percent and 17.5 percent in the placebo group.\textsuperscript{4} In the two studies, approximately 6 out of 10 patients treated with bimekizumab achieved ASDAS<2.1 at Week 52.\textsuperscript{1}

- **Inflammation:** Sustained reduction of objective inflammatory signs in both sacroiliac joints and the spine was observed in nr-axSpA and AS patients treated with bimekizumab vs. placebo as assessed by magnetic resonance imaging at Week 16 and Week 52, an exploratory endpoint.\textsuperscript{4,5}

In addition, in pooled data from BE MOBILE 1 and BE MOBILE 2, at Week 16, the proportion of patients developing a uveitis event was lower with bimekizumab (0.6 per cent) compared to placebo (4.6 percent). The
incidence of uveitis remained low with long-term treatment with bimekizumab (1.2/100 patient-years in the pooled Phase 2/3 studies).\(^1\)

“Today’s approval of a new treatment option for axial spondyloarthritis is welcome news to the European rheumatology community. In phase 3 clinical studies a greater proportion of patients treated with bimekizumab, compared with placebo, achieved high treatment targets with significant improvement in signs, symptoms and measures of disease activity across the full spectrum of disease, including non-radiographic and radiographic populations,” said Professor Désirée van der Heijde, Professor of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.

The most frequently reported TEAEs (3 percent or more in any bimekizumab group in either trial) up to Week 16 were nasopharyngitis, upper respiratory tract infection, pharyngitis, diarrhoea, headache and oral candidiasis.\(^4\)

Notes to editors:
About BE OPTIMAL and BE COMPLETE
The safety and efficacy of bimekizumab (160 mg every four weeks) were evaluated in adult patients with active psoriatic arthritis (PsA) in two multicentre, randomized, double-blind, placebo-controlled studies (BE OPTIMAL and BE COMPLETE).\(^1,2,3\) The BE OPTIMAL study evaluated 852 patients not previously exposed to any biologic disease-modifying anti-rheumatic drug (bDMARD-naïve) for the treatment of psoriasis or psoriatic arthritis.\(^2\) The BE COMPLETE study evaluated 400 patients with an inadequate response or intolerance to treatment with one or two tumour necrosis factor alpha inhibitors (TNFi-IR) for either psoriatic arthritis or psoriasis.\(^3\) Detailed findings from the BE OPTIMAL and BE COMPLETE studies are published in The Lancet.\(^2,3\)

About BE MOBILE 1 and BE MOBILE 2
The efficacy and safety of bimekizumab (160 mg every four weeks) were evaluated in 586 adult patients with active axial spondyloarthritis (axSpA) in two multicenter, randomized, double-blind, placebo-controlled studies, one in non-radiographic axSpA (nr-axSpA; BE MOBILE 1) and one in ankylosing spondylitis (AS; BE MOBILE 2), also known as radiographic axSpA.\(^1,4\) The BE MOBILE 1 and BE MOBILE 2 studies evaluated 254 and 332 patients, respectively.\(^4\) Detailed findings from the BE MOBILE 1 and BE MOBILE 2 studies are published in the Annals of the Rheumatic Diseases.\(^4\)

About bimekizumab
Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.\(^1,6\) The therapeutic indications in the European Union are:

- **Plaque psoriasis:** Bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\(^1\)
- **Psoriatic arthritis:** Bimekizumab is indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).\(^1\)
- **Axial Spondyloarthritis:** Bimekizumab is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs) and for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.\(^1\)
BIMZELX® ▼ (bimekizumab) EU/EEA* Important Safety Information¹

The most frequently reported adverse reactions with bimekizumab were upper respiratory tract infections (14.5%, 14.6%, 16.3% in plaque psoriasis (PSO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), respectively) and oral candidiasis (7.3%, 2.3%, 3.7% in PSO, PsA and axSpA, respectively). Common adverse reactions (≥1/100 to <1/10) were oral candidiasis, tinea infections, ear infections, herpes simplex infections, oropharyngeal candidiasis, gastroenteritis, folliculitis, headache, rash, dermatitis and eczema, acne, injection site reactions, fatigue. Elderly may be more likely to experience certain adverse reactions such as oral candidiasis, dermatitis and eczema when using bimekizumab.

Bimekizumab is contraindicated in patients with hypersensitivity to the active substance or any of the excipients and in patients with clinically important active infections (e.g. active tuberculosis). Bimekizumab may increase the risk of infections. Treatment with bimekizumab must not be initiated in patients with any clinically important active infection. Patients treated with bimekizumab should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops an infection the patient should be carefully monitored. If the infection becomes serious or is not responding to standard therapy, treatment should be discontinued until the infection resolves. Prior to initiating treatment with bimekizumab, patients should be evaluated for tuberculosis (TB) infection. Bimekizumab should not be given in patients with active TB. Patients receiving bimekizumab should be monitored for signs and symptoms of active TB.

Cases of new or exacerbations of inflammatory bowel disease have been reported with bimekizumab. Bimekizumab is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, bimekizumab should be discontinued and appropriate medical management should be initiated. Serious hypersensitivity reactions including anaphylactic reactions have been observed with IL-17 inhibitors. If a serious hypersensitivity reaction occurs, administration of bimekizumab should be discontinued immediately and appropriate therapy initiated.

Live vaccines should not be given in patients treated with bimekizumab.

Please consult the summary of product characteristics in relation to other side effects, full safety and prescribing information.

European SmPC date of revision: June 2023.


*EU/EEA means European Union/European Economic Area

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
For further information, contact UCB:

Investor Relations
Antje Witte
T +32.2.559.94.14
e-mail antje.witte@ucb.com

Corporate Communications
Laurent Schots
T +32.2.559.92.64
e-mail laurent.schots@ucb.com

Brand Communications
Eimear O’Brien
T +32.2.559.92.71
e-mail eimear.obrien@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,700 people in approximately 40 countries, the company generated revenue of €5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

Forward looking statements
This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional

Date of preparation: June 2023
indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

UCB is providing this information, including forward-looking statements, only as of the date of this press release. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

References